Cytori Therapeutics, Inc. engages in developing cell therapies based on autologous adipose-derived stem and regenerative cells (ADRCs) to treat cardiovascular disease and repair soft tissue defects. It offers Celution 800 System on a pre-launch basis, which is used for certain soft tissue procedures, including breast reconstruction; sells StemSource cell banking line, encompassing three product configurations, to hospitals, plastic surgery clinics, tissue banks, and stem cell banking companies; and commercializes Puregraft System that is designed to streamline the fat graft preparation process by selectively washing and filtering the tissue to remove contaminants in a closed sterile field. The company also offers a range of ancillary products designed to optimize tissue harvest and graft delivery, including Celbrush, a surgical instrument for the precise delivery of micro droplets that is used by reconstructive and cosmetic surgeons for autologous fat grafting and cell-enriched fat grafting procedures; and instrumentation to optimize tissue harvest. In addition, it engages in clinical trails for the development of a pipeline of therapies by using ADRCs for the treatment of cardiovascular diseases, such as heart failure and heart attacks. The company markets its systems, instrumentations, and consumables directly, as well as through a network of distributors to surgeons and hospitals worldwide. Cytori Therapeutics, Inc. has a strategic development and manufacturing joint venture agreement, and other related agreements with Olympus Corporation. The company was founded in 1996 and is headquartered in San Diego, California.